Investments
5Portfolio Exits
2Funds
1Partners & Customers
10Cancer Research UK Web Traffic
Cancer Research UK Rank
Latest Cancer Research UK News
Jun 23, 2022
It’s carnival time in Buckingham on Saturday, June 25, when the Cancer Research UK Carnival comes to Embleton Way. By Hannah Richardson Thursday, 23rd June 2022, 11:52 am The day will start with a parade and end with a parade – but they will be very different in tone and content. Few of us have avoided being affected in some way by cancer, either directly or through friends or family members, and Saturday’s fundraising event is a chance to have fun at the same time as contributing to Cancer UK’s invaluable research into the disease. The fun will start with a colourful opening parade, whilst the Lanterns of Light parade at the end of the day will be a time to reflect and remember loved ones lost to cancer. Sign up to our daily newsletter Sign up Submitting... This site is protected by reCAPTCHA and the Google Privacy Notice and Terms of Service apply. Volunteers Cath Stroud and Linda Woodham sell Candle of Hope bags at the 2018 Cancer Research UK Relay for Life in Buckingham The carnival will be opened at 10.30am by well-known local figure Ken Parker and his guide dog, Henry, after which the first lap undertaken by everyone who can be there to make it a celebration and fitting way to start the fun of the day. The Ferris wheel will provide unique views over Buckingham , and there will be inflatables for all ages of children, plus a variety of food outlets, games, traditional stalls and sideshows including a tombola. Children’s team relays will take place in the arena from noon to 2.30pm. Relays will be in teams of four children in different age groups and children need to be registered for the various heats before noon on the day. As well as the activities around the arena, a programme of music will be on offer, starting with the Adele Peters’ Singers and Dancers at 2.30pm. Following on at 4pm will be The Winslow Concert Band, 5pm The Buckingham Ukulele Group and 6.15pm The Dhol Show. The 60’s Jukebox band will end the day’s fun and enjoyment with a range of classics from the 1960s. This will be followed by a change of mood, with the Lanterns of Light Parade taking place after a brief ceremony of music and words at 10.15pm. Those familiar with Buckingham’s previous Relay for Life events, held over 14 years at Bourton Meadow Academy in aid of Cancer Research UK , will remember the similar Candle of Hope ceremony. Lanterns will be available at the carnival to dedicate to loved ones lost or those still battling bravely.
Cancer Research UK Investments
5 Investments
Cancer Research UK has made 5 investments. Their latest investment was in BioCaptiva as part of their Seed VC on June 6, 2022.
Cancer Research UK Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/2/2022 | Seed VC | BioCaptiva | $2.64M | Yes | 2 | |
9/6/2021 | Seed VC | |||||
1/4/2019 | Grant | |||||
1/4/2019 | Grant | |||||
10/5/2016 | Series A |
Date | 6/2/2022 | 9/6/2021 | 1/4/2019 | 1/4/2019 | 10/5/2016 |
---|---|---|---|---|---|
Round | Seed VC | Seed VC | Grant | Grant | Series A |
Company | BioCaptiva | ||||
Amount | $2.64M | ||||
New? | Yes | ||||
Co-Investors | |||||
Sources | 2 |
Cancer Research UK Portfolio Exits
2 Portfolio Exits
Cancer Research UK has 2 portfolio exits. Their latest portfolio exit was Monte Rosa Therapeutics on June 24, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
6/24/2021 | IPO | 17 | |||
Date | 6/24/2021 | |
---|---|---|
Exit | IPO | |
Companies | ||
Valuation | ||
Acquirer | ||
Sources | 17 |
Cancer Research UK Fund History
1 Fund History
Cancer Research UK has 1 fund, including SV7 Health Impact Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
7/2/2019 | SV7 Health Impact Fund | $252M | 1 |
Closing Date | 7/2/2019 |
---|---|
Fund | SV7 Health Impact Fund |
Fund Type | |
Status | |
Amount | $252M |
Sources | 1 |
Cancer Research UK Partners & Customers
10 Partners and customers
Cancer Research UK has 10 strategic partners and customers. Cancer Research UK recently partnered with Lineage Cell Therapeutics on April 4, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
4/13/2022 | Partner | United States | Lineage Cell Therapeutics , Inc. 's clinical programs are in markets with billion dollar opportunities and include four allogeneic product candidates : OpRegen , a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration , which is now being developed under a worldwide collaboration with Roche and Genentech , a member of the Roche ; OPC1 , an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries ; VAC2 , a dendritic cell therapy produced from Lineage Cell Therapeutics , Inc. 's VAC technology platform for immuno-oncology and infectious disease , currently in Phase 1 clinical development for the treatment of non-small cell lung cancer and ANP1 , an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy . | 4 | |
2/3/2022 | Partner | United Kingdom | Wigan Warriors reveal charity third kit featuring Cancer Research UK for the 2022 season Rachael Hodgkinson , from Cancer Research UK , said : `` We are really excited about working in partnership with Wigan Warriors . | 1 | |
6/23/2021 | Partner | United States | Under the terms of the clinical development partnership , Cancer Research UK 's Centre for Drug Development will fund , sponsor and conduct the first-in-human Phase 1/2a clinical trial of ALETA-001 , which will be led by Dr Amit Patel 's Cellular and CAR-T therapies team at The Christie NHS Foundation Trust in Manchester , UK . | 2 | |
6/23/2021 | Partner | ||||
3/3/2021 | Partner |
Date | 4/13/2022 | 2/3/2022 | 6/23/2021 | 6/23/2021 | 3/3/2021 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | United States | United Kingdom | United States | ||
News Snippet | Lineage Cell Therapeutics , Inc. 's clinical programs are in markets with billion dollar opportunities and include four allogeneic product candidates : OpRegen , a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration , which is now being developed under a worldwide collaboration with Roche and Genentech , a member of the Roche ; OPC1 , an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries ; VAC2 , a dendritic cell therapy produced from Lineage Cell Therapeutics , Inc. 's VAC technology platform for immuno-oncology and infectious disease , currently in Phase 1 clinical development for the treatment of non-small cell lung cancer and ANP1 , an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy . | Wigan Warriors reveal charity third kit featuring Cancer Research UK for the 2022 season Rachael Hodgkinson , from Cancer Research UK , said : `` We are really excited about working in partnership with Wigan Warriors . | Under the terms of the clinical development partnership , Cancer Research UK 's Centre for Drug Development will fund , sponsor and conduct the first-in-human Phase 1/2a clinical trial of ALETA-001 , which will be led by Dr Amit Patel 's Cellular and CAR-T therapies team at The Christie NHS Foundation Trust in Manchester , UK . | ||
Sources | 4 | 1 | 2 |
Cancer Research UK Team
2 Team Members
Cancer Research UK has 2 team members, including former Chief Financial Officer, Rita Akushie.
Name | Work History | Title | Status |
---|---|---|---|
Mel Nurse | Founder | Current | |
Rita Akushie | Chief Financial Officer | Former |
Name | Mel Nurse | Rita Akushie |
---|---|---|
Work History | ||
Title | Founder | Chief Financial Officer |
Status | Current | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.